-
Je něco špatně v tomto záznamu ?
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party
A. Bazarbachi, M. Labopin, E. Angelucci, Z. Gülbas, H. Ozdogu, M. Arat, L. de Rosa, R. Pastano, P. Pioltelli, R. Montserrat, M. Martino, F. Ciceri, Y. Koç, G. Socié, D. Blaise, C. Herrera, Y. Chalandon, P. Bernasconi, G. Marotta, L. Castagna, A....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Elsevier Open Access Journals
od 1998-06-01 do Před 1 rokem
Elsevier Open Archive Journals
od 1998-06-01 do Před 1 rokem
- MeSH
- akutní myeloidní leukemie * MeSH
- cyklofosfamid terapeutické užití MeSH
- dospělí MeSH
- haploidentická transplantace MeSH
- kostní dřeň MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfoblastická leukemie-lymfom z prekurzorových T-buněk * MeSH
- mladiství MeSH
- mladý dospělý MeSH
- nemoc štěpu proti hostiteli * prevence a kontrola MeSH
- přežití po terapii bez příznaků nemoci MeSH
- příprava pacienta k transplantaci MeSH
- retrospektivní studie MeSH
- senioři MeSH
- T-lymfocyty MeSH
- transplantace hematopoetických kmenových buněk * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Allogeneic hematopoietic cell transplantation (HCT) is recommended in high-risk patients with T cell acute lymphoblastic leukemia (T-ALL). For patients without an HLA-identical donor, haploidentical (haplo-) HCT is becoming the leading source of stem cell donation. However, data are scarce on predictive factors for outcome in that setting. We identified 122 adults (20% female; median age, 31 years; range, 18 to 68 years) with T-ALL who underwent haplo-HCT with post-transplantation cyclophosphamide (ptCy) between 2010 and 2017. The median duration of follow-up of living patients was 23 months. The 2-year incidences of relapse and nonrelapse mortality were 45% and 21%, respectively. The 2-year leukemia-free survival (LFS), overall survival (OS), and graft-versus-host disease, relapse-free survival (GRFS) were 34%, 42%, and 27%, respectively. The 2-year LFS and OS were highly influenced by disease status at transplantation, being 49% and 55%, respectively, for patients in first complete remission (CR1); 34% and 50%, respectively, for those in second CR (CR2); and 8% and 12%, respectively, for patients with active disease. On multivariate analysis, only disease status was found to affect LFS and OS. Transplantation in CR2 negatively affected LFS, whereas active disease at the time of haplo-HCT negatively affected LFS and OS. In conclusion, haplo-HCT with ptCy produced encouraging results in this challenging disease, particularly when performed in patients in CR. Despite the limitation of the small sample size, our results were not affected by the type of conditioning, calling into question the need for total body irradiation-based myeloablative conditioning in that setting.
Adult Bone Marrow Transplantation Center Baskent University Adana Hospital Adana Turkey
Albert Alberts Stem Cell Transplantation Centre Netcare Pretoria East Hospital Pretoria South Africa
BMT Unit SC Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy
Bone Marrow Transplantation Department Anadolu Medical Center Hospital Kocaeli Turkey
Department of Hematology and BMT Ospedale S Camillo Forlanini Rome Italy
Department of hematology and oncology Medicana International Istanbul Turkey
Department of Hematology BM Hopital St Louis Paris France
Department of Hematology BMT Hopital St Antoine Paris France
Department of Hematology with University Transplantation Universitaria Policlinico Bari Bari Italy
Department of Internal Medicine 5 University Hospital Erlangen Erlangen Germany
EBMT Paris Study Office CEREST TC Hôpital Saint Antoine Paris France
Hematology and BMT Ospedale San Raffaele Milan Italy
Hematology and Stem Cell Transplant Unit Azienda Ospedaliera BMM 89100 Reggio Calabria Italy
Hematology and Transplant Center IRCCS Ospedale Policlinico San Martino Genoa Italy
Hematology and Transplant Center Pesaro Hospital Pesaro Italy
Hematology Clinic of the University of Milano Biocca Ospedale San Gerardo Monza Italy
Hematology ICANS Hopitaux Universitaires Strasbourg Strasbourg France
Hematology Service Institute of Hematology and Blood Transfusion Prague Czech Republic
Hematopoietic SCT Unit Florence Nightingale Sisli Hospital Istanbul Turkey
Humanitas Clinical and Research Center IRCCS Department of Medical Oncology and Hematology
Onco Hematology Division European Institute of Oncology IRCCS Milan Italy
Stem Cell Transplant and Cellular Therapy Unit University Hospital Siena Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020563
- 003
- CZ-PrNML
- 005
- 20240528153237.0
- 007
- ta
- 008
- 210728s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bbmt.2020.01.003 $2 doi
- 035 __
- $a (PubMed)31926364
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Bazarbachi, Ali $u Bone Marrow Transplant Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: Bazarbac@aub.edu.lb
- 245 10
- $a Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party / $c A. Bazarbachi, M. Labopin, E. Angelucci, Z. Gülbas, H. Ozdogu, M. Arat, L. de Rosa, R. Pastano, P. Pioltelli, R. Montserrat, M. Martino, F. Ciceri, Y. Koç, G. Socié, D. Blaise, C. Herrera, Y. Chalandon, P. Bernasconi, G. Marotta, L. Castagna, A. McDonald, G. Visani, P. Carluccio, A. Vitek, C. Simand, B. Afanasyev, W. Rösler, JL. Diez-Martin, A. Nagler, E. Brissot, S. Giebel, M. Mohty
- 520 9_
- $a Allogeneic hematopoietic cell transplantation (HCT) is recommended in high-risk patients with T cell acute lymphoblastic leukemia (T-ALL). For patients without an HLA-identical donor, haploidentical (haplo-) HCT is becoming the leading source of stem cell donation. However, data are scarce on predictive factors for outcome in that setting. We identified 122 adults (20% female; median age, 31 years; range, 18 to 68 years) with T-ALL who underwent haplo-HCT with post-transplantation cyclophosphamide (ptCy) between 2010 and 2017. The median duration of follow-up of living patients was 23 months. The 2-year incidences of relapse and nonrelapse mortality were 45% and 21%, respectively. The 2-year leukemia-free survival (LFS), overall survival (OS), and graft-versus-host disease, relapse-free survival (GRFS) were 34%, 42%, and 27%, respectively. The 2-year LFS and OS were highly influenced by disease status at transplantation, being 49% and 55%, respectively, for patients in first complete remission (CR1); 34% and 50%, respectively, for those in second CR (CR2); and 8% and 12%, respectively, for patients with active disease. On multivariate analysis, only disease status was found to affect LFS and OS. Transplantation in CR2 negatively affected LFS, whereas active disease at the time of haplo-HCT negatively affected LFS and OS. In conclusion, haplo-HCT with ptCy produced encouraging results in this challenging disease, particularly when performed in patients in CR. Despite the limitation of the small sample size, our results were not affected by the type of conditioning, calling into question the need for total body irradiation-based myeloablative conditioning in that setting.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a kostní dřeň $7 D001853
- 650 _2
- $a cyklofosfamid $x terapeutické užití $7 D003520
- 650 _2
- $a přežití po terapii bez příznaků nemoci $7 D018572
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nemoc štěpu proti hostiteli $x prevence a kontrola $7 D006086
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a akutní myeloidní leukemie $7 D015470
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a lymfoblastická leukemie-lymfom z prekurzorových T-buněk $7 D054218
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a T-lymfocyty $7 D013601
- 650 _2
- $a příprava pacienta k transplantaci $7 D019172
- 650 _2
- $a haploidentická transplantace $7 D000075442
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Labopin, Myriam $u EBMT Paris Study Office/CEREST-TC, Hôpital Saint Antoine, Paris, France
- 700 1_
- $a Angelucci, Emanuele $u Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 700 1_
- $a Gülbas, Zafer $u Bone Marrow Transplantation Department, Anadolu Medical Center Hospital, Kocaeli, Turkey
- 700 1_
- $a Ozdogu, Hakan $u Adult Bone Marrow Transplantation Center, Baskent University Adana Hospital, Adana, Turkey
- 700 1_
- $a Arat, Mutlu $u Hematopoietic SCT Unit, Florence Nightingale Sisli Hospital, Istanbul, Turkey
- 700 1_
- $a de Rosa, Luca $u Department of Hematology and BMT, Ospedale S. Camillo-Forlanini, Rome, Italy
- 700 1_
- $a Pastano, Rocco $u Onco-Hematology Division, European Institute of Oncology IRCCS, Milan, Italy
- 700 1_
- $a Pioltelli, Pietro $u Hematology Clinic of the University of Milano-Biocca, Ospedale San Gerardo, Monza, Italy
- 700 1_
- $a Montserrat, Rovira $u Hospital Clinic, BMT Unit, Hematology Department, Institute of Hematology & Oncology. Institut d'Investigació Biomèdica August Pi I Sunyer, University of Barcelona, Institut Josep Carreras, Barcelona, Spain
- 700 1_
- $a Martino, Massimo $u Hematology and Stem Cell Transplant Unit, Azienda Ospedaliera BMM, 89100 Reggio Calabria, Italy
- 700 1_
- $a Ciceri, Fabio $u Hematology and BMT, Ospedale San Raffaele, Milan, Italy
- 700 1_
- $a Koç, Yener $u Department of hematology and oncology, Medicana International, Istanbul, Turkey
- 700 1_
- $a Socié, Gerard $u Department of Hematology-BM, Hopital St. Louis, Paris, France
- 700 1_
- $a Blaise, Didier $u Transplant and Cellular Immunotherapy Program, Department of Hematology, CRCM, Aix Marseille University, CNRS, INSERM, Institut Paoli Calmettes, Marseille, France
- 700 1_
- $a Herrera, Concepcion $u Department of Hematology, Reina Sofía University Hospital, Biomedical Research of Córdoba, University of Córdoba, Cordoba, Spain
- 700 1_
- $a Chalandon, Yves $u Hematology Division, Department of Oncology, Hôpitaux Universitaires de Genève and Faculty of Medicine, University of Geneva, Geneva, Switzerland
- 700 1_
- $a Bernasconi, Paolo $u BMT Unit, SC Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 700 1_
- $a Marotta, Giuseppe $u Stem Cell Transplant and Cellular Therapy Unit, University Hospital, Siena, Italy
- 700 1_
- $a Castagna, Luca $u Humanitas Clinical and Research Center - IRCCS, Department of Medical Oncology and Hematology
- 700 1_
- $a McDonald, Andrew $u Albert Alberts Stem Cell Transplantation Centre, Netcare Pretoria East Hospital, Pretoria, South Africa
- 700 1_
- $a Visani, Guiseppe $u Hematology and Transplant Center, Pesaro Hospital, Pesaro, Italy
- 700 1_
- $a Carluccio, Paola $u Department of Hematology with University Transplantation, Universitaria Policlinico Bari, Bari, Italy
- 700 1_
- $a Vitek, Antonin $u Hematology Service, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Simand, Célestine $u Hematology, ICANS-Hopitaux Universitaires Strasbourg, Strasbourg, France
- 700 1_
- $a Afanasyev, Boris $u Raisa Gorbacheva Memorial Research Institute for Paediatric Oncology, Hematology, and Transplantation. First State Pavlov Medical University of St Petersburg, St Petersburg, Russia
- 700 1_
- $a Rösler, Wolf $u Department of Internal Medicine 5, University Hospital Erlangen, Erlangen, Germany
- 700 1_
- $a Diez-Martin, J L $u Department of Hematology, Hospital General Universitario Gregorio Marañon, Instituto de investigación sanitaria Gregorio Marañon, Departament of Medicine, Universidad Complutense, Madrid, Spain
- 700 1_
- $a Nagler, Arnon $u Division of Hematology and the Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel
- 700 1_
- $a Brissot, Eolia $u Department of Hematology-BMT, Hopital St Antoine, Paris, France
- 700 1_
- $a Giebel, Sebastian $u Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Institute Oncology Centre, Gliwice Branch, Gliwice, Poland
- 700 1_
- $a Mohty, Mohamad $u Department of Hematology-BMT, Hopital St Antoine, Paris, France $7 xx0317729
- 773 0_
- $w MED00008579 $t Biology of blood and marrow transplantation $x 1523-6536 $g Roč. 26, č. 5 (2020), s. 936-942
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31926364 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20240528153234 $b ABA008
- 999 __
- $a ok $b bmc $g 1691187 $s 1141009
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 26 $c 5 $d 936-942 $e 20200109 $i 1523-6536 $m Biology of blood and marrow transplantation $n Biol Blood Marrow Transplant $x MED00008579
- LZP __
- $a Pubmed-20210728
